MedTrace Logo

Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy

NCT04238884 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2020-01-23

No results posted yet for this study

Summary

This is a phase IV pragmatic, multicentre, randomised, simple-blind, parallel arm, centre-stratified clinical trial. The main objective is to compare efficiency of voriconazole preemptive genotyping strategy, compared with routine practice.

Conditions

  • Invasive Fungal Infections

Interventions

DRUG

Voriconazole preemptive genotyping strategy

The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.

DRUG

Voriconazole clinical practice

The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice

Sponsors & Collaborators

  • Instituto de Investigación Hospital Universitario La Paz

    lead OTHER

Principal Investigators

  • Alberto M Borobia, MD, PhD · La Paz University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-02
Primary Completion
2020-01-18
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04238884 on ClinicalTrials.gov